Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes
In addition to its effects on insulin, GIP plays a crucial role in fat accumulation by promoting the activity of adipocyte-expressed lipoprotein lipase and promoting bone formation by preventing osteoclast apoptosis, as evidenced by the thinner bone trabeculae seen in mice lacking GIP receptors [20,21,22]
Tirzepatide vs semaglutide which is better for weight loss
For proteins that met the assumption of a normal distribution on a group basis, the statistical difference between the groups was evaluated via two-sample t -tests, whereas for proteins that did not meet the assumption of a normal distribution on at least one group basis, the statistical difference between the groups was evaluated via the MannWhitney U test